Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 27:2020:1936960.
doi: 10.1155/2020/1936960. eCollection 2020.

Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network

Antonio Vitale  1 , Jurgen Sota  1 , Laura Obici  2 , Nicola Ricco  1 , Maria Cristina Maggio  3 , Marco Cattalini  4 , Piero Ruscitti  5 , Francesco Caso  6 , Raffaele Manna  7 , Ombretta Viapiana  8 , Valeria Caggiano  1 , Giacomo Emmi  9 , Antonella Insalaco  10 , Davide Montin  11 , Francesco Licciardi  11 , Alessandra Soriano  12 , Lorenzo Dagna  13 , Carlo Salvarani  12 , Vittoria Lamacchia  14   15 , José Hernández-Rodríguez  16 , Roberto Giacomelli  5 , Bruno Frediani  1 , Alessandra Renieri  14   15 , Luca Cantarini  1
Affiliations

Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network

Antonio Vitale et al. Mediators Inflamm. .

Abstract

Objective: To analyze the potential role of colchicine monotherapy in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) in terms of control of clinical and laboratory manifestations.

Methods: Patients with TRAPS treated with colchicine monotherapy were retrospectively enrolled; demographic, clinical and therapeutic data were collected and statistically analysed after having clustered patients according to different times at disease onset, penetrance of mutations, dosage of colchicine, and different disease manifestations.

Results: 24 patients (14 males; 15 with pediatric disease onset) treated with colchicine monotherapy were enrolled. Colchicine resulted in a complete response in 3 (12.5%) cases, partial response in 14 (58.3%) patients, and lack of response in 7 (29.2%) patients. There were not significant differences in colchicine response between pediatric and adult disease onset (p = 0.42), between low- and high-penetrance mutations (p = 0.62), and according to different dosages (p = 0.66). No significant differences were identified in the frequency of specific disease manifestations between patients experiencing any response to colchicine and patients with lack of response.

Conclusions: Colchicine monotherapy is useful in a low percentage of TRAPS patients; nevertheless, it could be attempted in patients with milder phenotypes and at a lower risk of developing reactive amyloidosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Response to colchicine treatment distinguishing patients according to different age at disease onset (pediatric- versus adult-onset).
Figure 2
Figure 2
Response to colchicine administration according to different dosages employed (1 mg/day versus more than 1 mg/day).
Figure 3
Figure 3
Response to colchicine administration distinguishing patients according to the final response to nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids (CS), and biologic agents. In order to facilitate the reading of the histograms, patients experiencing complete response and partial response were meshed to be compared with patients presenting colchicine failure.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Rigante D., Lopalco G., Vitale A., et al. Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome. Clinical Rheumatology. 2014;33(9):1197–1207. doi: 10.1007/s10067-014-2722-z. - DOI - PubMed
    1. Cantarini L., Rigante D., Merlini G., et al. The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up. Seminars in Arthritis and Rheumatism. 2014;43(6):818–823. doi: 10.1016/j.semarthrit.2013.12.002. - DOI - PubMed
    1. Ruiz-Ortiz E., Iglesias E., Soriano A., et al. Disease phenotype and outcome depending on the age at disease onset in patients carrying the R92Q low-penetrance variant in TNFRSF1A gene. Frontiers in Immunology. 2017;8:p. 299. doi: 10.3389/fimmu.2017.00299. - DOI - PMC - PubMed
    1. Balci S., Kisla Ekinci R. M., Melek E., Atmis B., Bisgin A., Yilmaz M. Phenotypic variability in two patients with tumor necrosis factor receptor associated periodic fever syndrome emphasizes a rare manifestation: immunoglobulin A nephropathy. European Journal of Medical Genetics. 2020;63(4):p. 103780. doi: 10.1016/j.ejmg.2019.103780. - DOI - PubMed
    1. Gattorno M., Obici L., Cattalini M., et al. Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Annals of the Rheumatic Diseases. 2016;76(1):173–178. doi: 10.1136/annrheumdis-2015-209031. - DOI - PMC - PubMed

MeSH terms

Substances